Pausing Arthritis Drugs Failed to Boost Vaccine Response
Temporary medication holds did not improve COVID-19 vaccine antibodies but doubled the risk of arthritis flares.
Updated on Oct. 5, 2026 in Arthritis
Live Poll
Would you change your medication routine if it potentially made a vaccine more effective?
A clinical trial of 840 arthritis patients revealed that pausing targeted disease-modifying antirheumatic drugs (DMARDs) for two weeks prior to COVID-19 vaccination provided no immune benefit. Instead, the intervention significantly increased the likelihood of a disease flare compared to patients who maintained their medication schedule.
Why it matters
The findings challenge previous clinical assumptions that immunosuppressants might hinder vaccine efficacy in patients with chronic conditions. This trial provides critical evidence that stopping therapy may cause unnecessary physical distress without yielding a better protective response from the vaccine.
The trial, involving 840 patients with various forms of arthritis, recorded a geometric mean fold rise ratio for antibodies of 0.96 between the hold and control groups. Researchers noted a 31% loss to follow-up among the study population.
The players
University of Alabama at Birmingham
This institution serves as the primary base for the researchers who led the COVER clinical trial.
The details
Patients in the study group were instructed to pause their targeted DMARD therapy for two weeks, while control participants followed their usual medication schedule. Those who paused treatment faced an odds ratio of 2.27 for developing a new arthritis flare compared to those who did not.
Timeline
COVID-19 vaccines were broadly launched in early 2021.
Investigators began the COVER clinical trial in late 2021.
Data analysis for the clinical trial began in 2024.
The Big Picture
This study marks a significant shift in managing chronic disease protocols by utilizing findings from the COVER clinical trial. It challenges legacy hypotheses that assumed temporary immunosuppressant withdrawal was necessary for optimal immune response to vaccines.
Patients may find that maintaining their medication schedule is both safer and equally effective for vaccine response as pausing therapy. Individuals should consult their rheumatologist before altering any prescribed DMARD regimen to avoid the risk of clinically meaningful flares.
The takeaway
This evidence suggests that patients with rheumatic conditions can safely continue their existing medication schedules during vaccination cycles. Prioritizing disease stability over unproven immune gains may prevent unnecessary suffering for those managing chronic arthritis.
Further reading
For more information on the management of chronic joint inflammation, see the Arthritis section.
Live Poll
Would you change your medication routine if it potentially made a vaccine more effective?
